366 related articles for article (PubMed ID: 37180133)
1. Differential nasal swab cytology represents a valuable tool for therapy monitoring but not prediction of therapy response in chronic rhinosinusitis with nasal polyps treated with Dupilumab.
Danisman Z; Linxweiler M; Kühn JP; Linxweiler B; Solomayer EF; Wagner M; Wagenpfeil G; Schick B; Berndt S
Front Immunol; 2023; 14():1127576. PubMed ID: 37180133
[TBL] [Abstract][Full Text] [Related]
2. Dupilumab's impact on nasal citology: Real life experience after 1 year of treatment.
Gelardi M; Giancaspro R; Quaranta VN; La Gatta E; Ruzza A; Cassano M
Am J Otolaryngol; 2024; 45(4):104275. PubMed ID: 38574514
[TBL] [Abstract][Full Text] [Related]
3. The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP).
Hardison SA; Senior BA
J Otolaryngol Head Neck Surg; 2023 Sep; 52(1):64. PubMed ID: 37759322
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab (Dupixent
Jansen F; Becker B; Eden JK; Breda PC; Hot A; Oqueka T; Betz CS; Hoffmann AS
Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1741-1755. PubMed ID: 36242612
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps.
Dharmarajan H; Falade O; Lee SE; Wang EW
Int Forum Allergy Rhinol; 2022 Aug; 12(8):986-995. PubMed ID: 34919344
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab in chronic rhinosinusitis with nasal polyposis: current status, challenges, and future perspectives.
Li T; Yin J; Yang Y; Wang G; Zhang Y; Song X
Expert Rev Clin Immunol; 2023; 19(8):939-948. PubMed ID: 37378551
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary report.
Orlando P; Licci G; Kuitche D; Matucci A; Vultaggio A; Gallo O; Maggiore G
Eur Arch Otorhinolaryngol; 2024 Mar; 281(3):1317-1324. PubMed ID: 37910208
[TBL] [Abstract][Full Text] [Related]
8. Biologics for chronic rhinosinusitis.
Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
[TBL] [Abstract][Full Text] [Related]
9. The role of intranasal corticosteroids in chronic rhinosinusitis with nasal polyposis treated with dupilumab.
Pecorari G; Piazza F; Borgione M; Prizio C; Galli Della Mantica G; Garetto M; Gedda F; Riva G
Am J Otolaryngol; 2023; 44(5):103927. PubMed ID: 37245323
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab improves sleep quality in chronic rhinosinusitis with nasal polyps.
Riva G; Garetto M; Borgione M; Piazza F; Prizio C; Dellea D; Albera A; Canale A; Pecorari G
Am J Otolaryngol; 2024; 45(4):104310. PubMed ID: 38677148
[TBL] [Abstract][Full Text] [Related]
11. Platelet-to-lymphocyte ratio might predict the response to dupilumab treatment for patients with nasal polyposis.
Brkic FF; Liu DT; Rücklinger I; Campion NJ; Bartosik TJ; Vyskocil E; Stanek V; Tu A; Gangl K; Schneider S
J Otolaryngol Head Neck Surg; 2023 Nov; 52(1):75. PubMed ID: 38007429
[TBL] [Abstract][Full Text] [Related]
12. The role of serum macrophage migration inhibitory factor in preoperative prediction of chronic rhinosinusitis with nasal polyps endotypes.
Yuan X; Xie S; Jing Q; She Y; Jiang W; Zhang H; Xie Z
Int Immunopharmacol; 2021 Nov; 100():108084. PubMed ID: 34482268
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience.
Galletti C; Ragusa M; Sireci F; Ciodaro F; Barbieri MA; Giunta G; Grigaliute E; Immordino A; Lorusso F; Dispenza F; Freni F; Galletti F; Gallina S; La Mantia I; Galletti B
Am J Otolaryngol; 2024; 45(1):104106. PubMed ID: 37948824
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps.
Hoy SM
Drugs; 2020 May; 80(7):711-717. PubMed ID: 32240527
[TBL] [Abstract][Full Text] [Related]
16. Real-Life Experience of Monoclonal Antibody Treatments in Chronic Rhinosinusitis with Nasal Polyposis.
Meier EC; Schmid-Grendelmeier P; Steiner UC; Soyka MB
Int Arch Allergy Immunol; 2021; 182(8):736-743. PubMed ID: 33756474
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL).
De Corso E; Pasquini E; Trimarchi M; La Mantia I; Pagella F; Ottaviano G; Garzaro M; Pipolo C; Torretta S; Seccia V; Cantone E; Ciofalo A; Lucidi D; Fadda GL; Pafundi PC; Settimi S; Montuori C; Anastasi F; Pagliuca G; Ghidini A; Cavaliere C; Maffei M; Bussu F; Gallo S; Canevari FRM; Paludetti G; Galli J;
Allergy; 2023 Oct; 78(10):2669-2683. PubMed ID: 37203259
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
19. [Experience of biological therapy in severe forms of chronic rhinosinusitis with nasal polyps in the conditions of regional healthcare].
Larin RA; Mokeeva PP; Grishin AS
Vestn Otorinolaringol; 2023; 88(2):51-58. PubMed ID: 37184555
[TBL] [Abstract][Full Text] [Related]
20. Type 2 Biomarkers for the Indication and Response to Biologics in CRSwNP.
Guo CL; Liu FF; Wang DY; Liu Z
Curr Allergy Asthma Rep; 2023 Dec; 23(12):703-713. PubMed ID: 37987873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
